Meet us at J.P.Morgan Healthcare Conference
As we prepare to wrap up another exciting year for Aitia, we’re eagerly looking forward to a bustling 2024. For now, we’re gearing up for the J.P. Morgan conference, where our CEO, Colin Hill and President, COO, Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the […]
Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement WILMINGTON, Mass. & Somerville, Mass. – November 13, 2023: Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia, a leader in the application of Causal AI and […]
SfN Poster | Genes regulating cytoskeleton organization identified as neuro-common drivers of blood NfL change rate and disease-specific clinical progression in AI driven Digital Twins
X. SHEN, D. SHOKEEN, O. ISACSON, R. HARRISON, S.-Y. SHIN, J. LATOURELLE
Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia’s Digital Twins to be Presented at SfN 2023
Somerville, MA, November 8, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer’s Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from […]
Driving the Discovery and Clinical Development of the Next Generation of Alzheimer’s Disease Drugs: Join us at the CNS Summit 2023
We are thrilled to announce that Aitia will be participating in the CNS Summit 2023 conference. Colin Hill, will be joined by Rudolph Tanzi, Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, and Ole Isacson, Professor & Chair […]
CTAD Poster | Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins
Wenjun Zhu, So-Youn Shin, Jeanne Latourelle
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
Somerville, MA, October 19, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer’s Disease Digital Twins will be presented at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD), being held from October 24-27, 2023 in Boston. Aitia’s Digital […]
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]